Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

Stoke Therapeutics (STOK) Gains from Sales and Divestitures (2024)

Stoke Therapeutics has reported Gains from Sales and Divestitures over the past 1 years, most recently at $748238.0 for Q4 2024.

For Q4 2024, Gains from Sales and Divestitures changed N/A year-over-year to $748238.0; the TTM value through Dec 2024 reached $748238.0, changed N/A, while the annual FY2024 figure was $748238.0, N/A changed from the prior year.
Gains from Sales and Divestitures for Q4 2024 was $748238.0 at Stoke Therapeutics.
Over five years, Gains from Sales and Divestitures peaked at $748238.0 in Q4 2024 and troughed at $748238.0 in Q4 2024.